{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T20:05:24Z","timestamp":1760472324274},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1097\/hpc.0000000000000042","type":"journal-article","created":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T19:41:48Z","timestamp":1431718908000},"page":"53-61","source":"Crossref","is-referenced-by-count":13,"title":["The Real-World Treatment of Hemorrhages Associated With Dabigatran and Rivaroxaban"],"prefix":"10.1097","volume":"14","author":[{"given":"Lesley","family":"Pahs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Beavers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210126","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R2-1-20210126","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial.","volume":"363","author":"Connolly","year":"2010","journal-title":"N Engl J Med"},{"key":"R3-1-20210126","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"R4-1-20210126","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"R9-1-20210126","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization.","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"R11-1-20210126","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","article-title":"Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.","volume":"130","author":"Douxfils","year":"2012","journal-title":"Thromb Res"},{"key":"R12-1-20210126","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","article-title":"Impact of dabigatran on a large panel of routine or specific coagulation assays.","volume":"107","author":"Douxfils","year":"2012","journal-title":"Thromb Haemost"},{"key":"R14-1-20210126","doi-asserted-by":"crossref","first-page":"e78696","DOI":"10.1371\/journal.pone.0078696","article-title":"Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.","volume":"8","author":"Escolar","year":"2013","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"R15-1-20210126","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1002\/ajh.23202","article-title":"Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.","volume":"87","author":"Kaatz","year":"2012","journal-title":"Am J Hematol"},{"key":"R17-1-20210126","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","article-title":"Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.","volume":"108","author":"Marlu","year":"2012","journal-title":"Thromb Haemost"},{"key":"R18-1-20210126","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2146\/ajhp110725","article-title":"Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient.","volume":"69","author":"Miyares","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"R20-1-20210126","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1160\/TH12-05-0319","article-title":"New direct oral anticoagulants-current therapeutic options and treatment recommendations for bleeding complications.","volume":"108","author":"Miesbach","year":"2012","journal-title":"Thromb Haemost"},{"key":"R21-1-20210126","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1538-7836.2011.04498.x","article-title":"Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with nonvalvular atrial fibrillation from the RE-LY trial.","volume":"9","author":"Liesenfeld","year":"2011","journal-title":"J Thromb Haemost"},{"key":"R23-1-20210126","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R24-1-20210126","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity.","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"R25-1-20210126","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40266-013-0119-3","article-title":"Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation.","volume":"30","author":"Stollberger","year":"2013","journal-title":"Drugs Aging"},{"key":"R26-1-20210126","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1592\/phco.26.8.1091","article-title":"Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin.","volume":"26","author":"Dager","year":"2006","journal-title":"Pharmacotherapy"}],"container-title":["Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:40:41Z","timestamp":1620952841000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00132577-201506000-00001"}},"subtitle":["A Multicenter Evaluation"],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/hpc.0000000000000042","relation":{},"ISSN":["1535-282X"],"issn-type":[{"value":"1535-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}